1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Lu X, Yan CH, Yuan M, Wei Y, Hu G and Kang
Y: In vivo dynamics and distinct functions of hypoxia in primary
tumor growth and organotropic metastasis of breast cancer. Cancer
Res. 70:3905–3914. 2010. View Article : Google Scholar : PubMed/NCBI
|
3
|
Friedl P, Locker J, Sahai E and Segall JE:
Classifying collective cancer cell invasion. Nat Cell Biol.
14:777–783. 2012. View
Article : Google Scholar : PubMed/NCBI
|
4
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Nguyen DX, Bos PD and Massagué J:
Metastasis: from dissemination to organ-specific colonization. Nat
Rev Cancer. 9:274–284. 2009. View
Article : Google Scholar : PubMed/NCBI
|
6
|
Lu X and Kang Y: Organotropism of breast
cancer metastasis. J Mammary Gland Biol Neoplasia. 12:153–162.
2007. View Article : Google Scholar : PubMed/NCBI
|
7
|
Chan DA and Giaccia AJ: Hypoxia, gene
expression, and metastasis. Cancer Metastasis Rev. 26:333–339.
2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Nagelkerke A, Bussink J, Mujcic H, Wouters
BG, Lehmann S, Sweep FC and Span PN: Hypoxia stimulates migration
of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded
protein response. Breast Cancer Res. 15:R22013. View Article : Google Scholar : PubMed/NCBI
|
9
|
Krishnamachary B, Berg-Dixon S, Kelly B,
et al: Regulation of colon carcinoma cell invasion by
hypoxia-inducible factor 1. Cancer Res. 63:1138–1143.
2003.PubMed/NCBI
|
10
|
Muñoz-Nájar UM, Neurath KM, Vumbaca F and
Claffey KP: Hypoxia stimulates breast carcinoma cell invasion
through MT1-MMP and MMP-2 activation. Oncogene. 25:2379–2392. 2006.
View Article : Google Scholar
|
11
|
Zhong H, De Marzo AM, Laughner E, et al:
Overexpression of hypoxia-inducible factor 1alpha in common human
cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
12
|
Oakes SA and Korsmeyer SJ: Untangling the
web: mitochondrial fission and apoptosis. Dev Cell. 7:460–462.
2004. View Article : Google Scholar : PubMed/NCBI
|
13
|
Szabadkai G, Simoni AM, Chami M,
Wieckowski MR, Youle RJ and Rizzuto R: Drp-1-dependent division of
the mitochondrial network blocks intraorganellar Ca2+
waves and protects against Ca2+-mediated apoptosis. Mol
Cell. 16:59–68. 2004. View Article : Google Scholar : PubMed/NCBI
|
14
|
Shaw JM and Nunnari J: Mitochondrial
dynamics and division in budding yeast. Trends Cell Biol.
12:178–184. 2002. View Article : Google Scholar : PubMed/NCBI
|
15
|
Han XJ, Lu YF, Li SA, Tomizawa K, Takei K,
Matsushita M and Matsui H: Involvement of calcineurin in
glutamate-induced mitochondrial dynamics in neurons. Neurosci Res.
60:114–119. 2008. View Article : Google Scholar
|
16
|
Chan DC: Mitochondrial fusion and fission
in mammals. Annu Rev Cell Dev Biol. 22:79–99. 2006. View Article : Google Scholar : PubMed/NCBI
|
17
|
Grandemange S, Herzig S and Martinou JC:
Mitochondrial dynamics and cancer. Semin Cancer Biol. 19:50–56.
2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Zhao J, Zhang J, Yu M, et al:
Mitochondrial dynamics regulates migration and invasion of breast
cancer cells. Oncogene. 32:4814–4824. 2013. View Article : Google Scholar
|
19
|
Wong E and Giandomenico CM: Current status
of platinum-based antitumor drugs. Chem Rev. 99:2451–2466. 1999.
View Article : Google Scholar
|
20
|
Milacic V, Fregona D and Dou QP: Gold
complexes as prospective metal-based anticancer drugs. Histol
Histopathol. 23:101–108. 2008.
|
21
|
Chen H, Hardy TM and Tollefsbol TO:
Epigenomics of ovarian cancer and its chemoprevention. Front Genet.
2:672011. View Article : Google Scholar
|
22
|
Santin G, Piccolini VM, Barni S, et al:
Mitochondrial fusion: a mechanism of cisplatin-induced resistance
in neuroblastoma cells? Neurotoxicology. 34:51–60. 2013. View Article : Google Scholar
|
23
|
Farrand L, Byun S, Kim JY, et al:
Piceatannol enhances cisplatin sensitivity in ovarian cancer via
modulation of p53, X-linked inhibitor of apoptosis protein (XIAP),
and mitochondrial fission. J Biol Chem. 288:23740–23750. 2013.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Kurbacher CM, Wagner U, Kolster B,
Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C)
improves the antineoplastic activity of doxorubicin, cisplatin, and
paclitaxel in human breast carcinoma cells in vitro. Cancer Lett.
103:183–189. 1996. View Article : Google Scholar : PubMed/NCBI
|
25
|
Wan YY, Zhang JF, Yang ZJ, et al:
Involvement of Drp1 in hypoxia-induced migration of human
glioblastoma U251 cells. Oncol Rep. 32:619–626. 2014.PubMed/NCBI
|
26
|
Han XJ, Lu YF, Li SA, et al: CaM kinase I
alpha-induced phosphorylation of Drp1 regulates mitochondrial
morphology. J Cell Biol. 182:573–585. 2008. View Article : Google Scholar : PubMed/NCBI
|
27
|
Han XJ, Tomizawa K, Fujimura A, Ohmori I,
Nishiki T, Matsushita M and Matsui H: Regulation of mitochondrial
dynamics and neurodegenerative diseases. Acta Med Okayama. 65:1–10.
2011.PubMed/NCBI
|
28
|
Park J and Choi C: Contribution of
mitochondrial network dynamics to intracellular ROS signaling.
Commun Integr Biol. 5:81–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
29
|
Twig G and Shirihai OS: The interplay
between mitochondrial dynamics and mitophagy. Antioxid Redox
Signal. 14:1939–1951. 2011. View Article : Google Scholar :
|
30
|
Zhang Y, Liu Q, Wang F, et al: Melatonin
antagonizes hypoxia-mediated glioblastoma cell migration and
invasion via inhibition of HIF-1α. J Pineal Res. 55:121–130. 2013.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Chatterjee A, Dasgupta S and Sidransky D:
Mitochondrial subversion in cancer. Cancer Prev Res (Phila).
4:638–654. 2011. View Article : Google Scholar
|
32
|
Galluzzi L, Morselli E, Kepp O, et al:
Mitochondrial gateways to cancer. Mol Aspects Med. 31:1–20. 2010.
View Article : Google Scholar
|
33
|
Ralph SJ, Rodríguez-Enríquez S, Neuzil J,
Saavedra E and Moreno-Sánchez R: The causes of cancer revisited:
‘mitochondrial malignancy’ and ROS-induced oncogenic transformation
- why mitochondria are targets for cancer therapy. Mol Aspects Med.
31:145–170. 2010. View Article : Google Scholar : PubMed/NCBI
|
34
|
Wallace DC: Mitochondria and cancer. Nat
Rev Cancer. 12:685–698. 2012. View Article : Google Scholar : PubMed/NCBI
|
35
|
Rehman J, Zhang HJ, Toth PT, et al:
Inhibition of mitochondrial fission prevents cell cycle progression
in lung cancer. FASEB J. 26:2175–2186. 2012. View Article : Google Scholar : PubMed/NCBI
|
36
|
Hagenbuchner J, Kuznetsov AV, Obexer P and
Ausserlechner MJ: BIRC5/Survivin enhances aerobic glycolysis and
drug resistance by altered regulation of the mitochondrial
fusion/fission machinery. Oncogene. 32:4748–4757. 2013. View Article : Google Scholar
|
37
|
Qian W, Wang J and Van Houten B: The role
of dynamin-related protein 1 in cancer growth: a promising
therapeutic target? Expert Opin Ther Targets. 17:997–1001. 2013.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Kushnareva Y, Andreyev AY, Kuwana T and
Newmeyer DD: Bax activation initiates the assembly of a multimeric
catalyst that facilitates Bax pore formation in mitochondrial outer
membranes. PLoS Biol. 10:e10013942012. View Article : Google Scholar : PubMed/NCBI
|
39
|
Ma J, Zhang Q, Chen S, et al:
Mitochondrial dysfunction promotes breast cancer cell migration and
invasion through HIF1α accumulation via increased production of
reactive oxygen species. PLoS One. 8:e694852013. View Article : Google Scholar
|
40
|
Tochhawng L, Deng S, Pervaiz S and Yap CT:
Redox regulation of cancer cell migration and invasion.
Mitochondrion. 13:246–253. 2013. View Article : Google Scholar
|